Semaglutide can help shed a considerable amount of weight: studies report an average weight loss of 10 to 15 per cent thanks to the active ingredient
The Wegovy (semaglutide) tablet is taken once daily and is intended for obese adults with a body mass index (BMI) of 30 or higher
Translational success will require (i) rigorous preclinical-to-clinical pipelines that include long-term toxicity and biodistribution studies, (ii) GMP- compliant manufacturing to ensure reproducibility and scalability, (iii) adaptive trial designs capable of evaluating patient-specific nanotherapies, and (iv) clearer regulatory alignment across FDA/EMA to classify and approve multifunctional nanoplatforms
The market for such weight-loss treatments, which Novo Nordisk is targeting with anti-obesity treatment Wegovy, is forecast to reach $150 billion by the early 2030s
According to Britta Reierson, MD, FAAFP, Midwest/Central Medical Director at Knownwell, The best meal plan when taking GLP-1 medication focuses on nutrient-dense, whole foods that are high in protein and fiber
